All Wales National Audit 2013 f ACKD. Anaemia of CKD. Chris Brown SWW Renal Unit. David Jackson Anke Hagemi North Wales Renal Unit 10/21/2013 1

Size: px
Start display at page:

Download "All Wales National Audit 2013 f ACKD. Anaemia of CKD. Chris Brown SWW Renal Unit. David Jackson Anke Hagemi North Wales Renal Unit 10/21/2013 1"

Transcription

1 All Wales National Audit 2013 f ACKD Anaemia of CKD Chris Brown SWW Renal Unit David Jackson Anke Hagemi ABMU HB North Wales Renal Unit 10/21/2013 1

2 Governance: are reconfigured services robust? Contractual: inform procurement obligations Critical appraisal: what s done well or not? Defining National standards: registry shortfalls Practice development: consider our treatment approaches Future opportunities: procurement & clinical 2

3 Anaemia of Chronic Kidney Disease Treated when HB consistently below 10g/dl with: Iron repletion: Ferritin > 200 ng/ml TSAT >20% ESAs Hb g/dl Treatment is effective BUT expensive AND also labour intensive because of the need for tight target control HB: too low is harmful & too high harmful We need to use ESAs sparingly & with care 10/21/2013 3

4 Set by the UK Renal Association for: Hb Ferritin (shift 2011) TSAT Determined by the Renal Registry for: Hb Ferritin In HD and PD patients. All Wales audit 2012: Hb, Feritin, TSAT In Pre-dialysis & Tx 4

5 Audit of routine monthly / quarterly bloods March 2013 Inclusion/exclusion criteria Excel data proforma N = ~ 3000 patients (~ 2700 after QC) Analysis: compliance with national targets Excel calculator developed for analysis 10/21/2013 5

6 Inclusion: Haemodialysis = All pts Peritoneal / Tx / Pre-dialysis = only ESA pts Study MONTH Study PERIOD January February March ESA dose Venofer Cosmofer / Monofer / Ferinject / Rienso Blood results = latest recorded 10/21/2013 6

7 10/21/2013 7

8 10/21/2013 8

9 = 2 x Month mg 1gm 1gms = 1 x per day 1-gram 1g 1 g 10/21/2013 9

10 10/21/

11 Hospital No. Yes Yes yes Unit Hub Yes Yes Yes CKD Status Yes Yes Yes Date dialysis initiated Yes Yes No Incident vs Prevalent Yes Yes No ESA Brand Yes Yes Yes ESA Route Yes Yes Yes Weekly ESA dose Yes Yes Yes Freq of administration Yes Yes Yes Monthly / Quart. Iron dose Yes Yes No IV Iron brand Yes Yes No Supp. oral Iron Yes Yes No HB Yes Yes Yes Ferritin Yes Yes Yes TSAT Yes Yes N/A CRP Yes Yes No Pre and Post urea Yes Yes No URR Yes Yes No Vascular access Yes Yes No 10/21/

12 10/21/

13 % Patients in Hb range Mean Hb (g/dl) 100% Patient Numbers % % % % 50% % % 20% 56.2% 46.4% 56.0% 55.1% % above target (>12g/dl) % in target (10-12g/dl) 10% 59.7% 7.0 % below target (<10g/dl) 0% 49.4% Bangor Cardiff Rhyl Swansea Wrexham All Wales 6.0 Mean

14 10/21/

15 % Patients in Hb range Mean Hb (g/dl) 100% 90% 80% 70% Patient numbers Bangor % Cardiff % Rhyl % Swansea % Wrexham % All Wales % 60% % % % 20% 10% 62.2% 56.4% 57.1% 60.9% 65.6% 59.2% % above target (>12g/dl) % in target (10-12g/dl) % below target (<10g/dl) 0% Bangor Cardiff Rhyl Swansea Wrexham All Wales 6.0 Mean

16 Swansea Bangor Rhyl Wales Cardiff Wrex 61% 62% 57 % Wales % 66% 59% 56% 60% 46 % Wales % 50% 55% 67% 59% 58 % RR % 49% 59% 10/21/

17 % Patients in ferritin range Mean Ferritin ng/ml 100% 90% 80% 70% Patient Numbers % 2.6% 13.5% 12.6% 11.7% 12.9% 11.0% 7.7% 17.9% 27.0% 22.3% 26.4% Bangor % Cardiff % Rhyl % Swansea % Wrexham 93 98% All Wales % 60% % % 30% 20% 62.8% % % 41.8% 55.6% % above target (>800ng/ml) % above target ( ng/ml) % in target ( ng/ml) % below target ( ng/ml) 10% 0% 18.9% 13.2% 17.6% 15.4% 55.4% 14.3% 2.7% 5.7% 1.4% 2.5% 3.3% 3.3% Bangor Cardiff Rhyl Swansea Wrexham All Wales % below target (<100ng/ml) Mean

18 Rhyl Cardiff Swansea Wales Bangor Wales % 100% 97% 94% 97% Wales % 100% 97% 91% 95% RR % 97% 96% 91% 95% Iron Dose mg mg mg mg 10/21/

19 Cardiff Rhyl Bangor Swansea Wales 63% 71% 55% 46% Wales % 57% 64% 54% 45% Wales % 64% 63% 58% 50% RR % 10/21/

20 Rhyl Bangor Swansea Cardiff Wales 2.6% 14% 13% 3.2% Wales % 2.9% 3% 7% 4.6% Wales % 10/21/

21 % Patients in TSAT range Mean TSAT % 100% 90% 80% 70% 60% Patient Number with test reult % 55.0% 85.6% 64.6% Bangor 74 0% Cardiff 456 0% Rhyl % Swansea % Wrexham 93 97% All-Wales % 50% 40% 30% % in target (>=20% 20% 45.0% 35.4% 10 % below target (<20%) 10% 19.5% 14.4% 0% 0.0% 0.0% 0.0% 0.0% Bangor Cardiff Rhyl Swansea Wrexham All-Wales 0 Mean

22 HB : Targets > UK benchmarks Consistent across Wales HB: Improvement from 2012 Ferritin: target > UK benchmarks Appropriate iron strategies Maintaining standards 2013 RRR looks bright Similarities: same outcomes Differences: management strategies 10/21/

23 % Patients in Hb range Mean Hb (g/dl) 100% 90% 80% 70% Patient Number Bangor % Cardiff % Rhyl 3 100% Swansea % Wrexham 2 100% All Wales % 60% % 40% % % % % % 61.5% 9.0 % above target (>12g/dl) 20% 8.0 % in target (10-12g/dl) 10% 7.0 % below target (<10g/dl) 0% 100.0% Bangor Cardiff Rhyl Swansea Wrexham All Wales 6.0 Mean

24 % Patients in ferritin range Mean Ferritin ng/ml 100% 90% 80% 70% Patient Number % 18.7% 32.0% Bangor % Cardiff 36 89% Rhyl 3 100% Swansea % Wrexham 2 100% All Wales 79 95% 60% % % % % 30% 20% 10% 0% 61.5% 25.0% % 24.0% 21.3% 20.0% 15.4% 21.9% 12.0% 14.7% 7.7% 100.0% Bangor Cardiff Rhyl Swansea Wrexham All Wales % above target (>800ng/ml) % above target ( ng/ml) % in target ( ng/ml) % below target ( ng/ml) % below target (<100ng/ml) Mean

25 % Patients in TSAT range Mean TSAT % 100% 90% 80% 70% Patient Numbers for test result % 32.0% 0.0% 37.9% Bangor 13 0% Cardiff 36 0% Rhyl 3 100% Swansea % Wrexham 2 50% All-Wales 79 37% 60% 50 50% 40% % 20% 10% % in target (>=20% % below target (<20%) 0% 0.0% 0.0% Bangor Cardiff Rhyl Swansea Wrexham All-Wales 0 Mean

26 Surly more Home HD patients achieve target? HB, Ferritin and TSAT: In target : Home HD < Unit HD This must be because they over achieve target? 10/21/

27 % Patients in Hb range Mean Hb (g/dl) 100% 90% 80% 70% Patient Bangor % Cardiff 43 98% Rhyl 8 100% Swansea 51 98% Wrexham % All Wales % 60% % % 54.8% % 56.0% 59.8% 9.0 % above target (>12g/dl) 20% 10% 70.0% 75.0% 75.0% % in target (10-12g/dl) % below target (<10g/dl) 0% Bangor Cardiff Rhyl Swansea Wrexham All Wales 6.0 Mean

28 % Patients in ferritin range Mean Ferritin ng/ml 100% 90% 80% 70% Patient Numbers % 11.6% 6.0% 13.0% 21.4% 20.9% Bangor % Cardiff 43 65% Rhyl 8 88% Swansea 51 84% Wrexham % All Wales % 60% 50% % 42.9% 48.0% % 20% 10% 0% % 66.7% 71.4% 19.0% 70.0% 9.3% 14.3% 16.7% 35.7% 7.0% 14.0% Bangor Cardiff Rhyl Swansea Wrexham All Wales % above target (>800ng/ml) % above target ( ng/ml) % in target ( ng/ml) % below target ( ng/ml) % below target (<100ng/ml) Mean

29 % Patients in TSAT range Mean TSAT % 100% 90% 80% 70% Patient Numbers % 63.8% Bangor 10 0% Cardiff 43 0% Rhyl 8 0% Swansea 51 92% Wrexham 12 0% All-Wales % 60% 50% % 15 30% 20% 10% 36.2% 36.2% 10 5 % in target (>=20% % below target (<20%) 0% 0.0% 0.0% 0.0% Bangor Cardiff Rhyl Swansea Wrexham All-Wales 0.0% 0 Mean

30 HB : Targets > UK benchmarks Less consistent across Wales (vs HD) HB: similar to 2012 Ferritin: New target by authorities Ferritin: target > UK benchmarks Significant improvement to /21/

31 10/21/

32 10/21/

33 Why repatriated to a tertiary care service? 10/21/

34 1. Increasing prevalence & patient no. Increasing recognition & referral 2. Tighter clinical targets 3. Increasing options & complexity 4. Increasing costs & need to reduce expenditure 10/21/

35 10/21/

36 % Patients in Hb range Mean Hb (g/dl) 100% 90% 80% 70% Patient Numbers Bangor 4 100% Cardiff 98 83% Rhyl 9 100% Swansea % Wrexham 0 #DIV/0! All Wales % 60% % 40% % % 75.0% 9.0 % above target (>12g/dl) 20% 59.3% 60.9% 60.7% 8.0 % in target (10-12g/dl) 10% 7.0 % below target (<10g/dl) 0% 0.0% Bangor Cardiff Rhyl Swansea Wrexham All Wales 6.0 Mean

37 % Patients in ferritin range Mean Ferritin ng/ml 100% 90% 80% 70% 0.0% 8.9% 11.1% 10.0% 9.4% 10.7% 11.1% 10.0% 10.4% 467 Patient Numbers Bangor 4 25% Cardiff 98 57% Rhyl 9 100% Swansea 46 87% Wrexham 0 #DIV/0! All Wales % 60% 50% 23.2% 23.2% % % 30.2% % 30% 0.0% 35.0% 25.5% % 10% 0% 33.9% 33.3% 10.0% 100.0% 0.0% 0.0% 0.0% % Bangor Cardiff Rhyl Swansea Wrexham All Wales % above target (>800ng/ml) % above target ( ng/ml) % in target ( ng/ml) % below target ( ng/ml) % below target (<100ng/ml) Mean

38 % Patients in TSAT range Mean TSAT % 100% 90% 80% 70% Patient Numbers % 67.5% 68.3% Bangor 4 25% Cardiff 98 0% Rhyl 9 0% Swansea 46 87% Wrexham 0 #DIV/0! All-Wales % 60% 50% % 15 30% 20% 10% 32.5% 31.7% 10 5 % in target (>=20% % below target (<20%) 0% 0.0% 0.0% Bangor Cardiff Rhyl Swansea Wrexham All-Wales 0.0% 0 Mean

39 % Patients in Hb range Mean Hb (g/dl) 100% 90% 80% 70% Patient Numbers Bangor % Cardiff % Rhyl % Swansea % Wrexham % All Wales % 60% % % % 64.7% 9.0 % above target (>12g/dl) 20% 10% 66.3% 73.2% 63.6% 65.2% 65.4% % in target (10-12g/dl) % below target (<10g/dl) 0% Bangor Cardiff Rhyl Swansea Wrexham All Wales 6.0 Mean

40 % Patients in ferritin range Mean Ferritin ng/ml 100% 90% 80% 70% 60% 50% % % Patient Numbers % 40.3% Bangor % Cardiff % Rhyl % Swansea % Wrexham % All Wales % 40% 30% % 60.7% % above target (>800ng/ml) % above target ( ng/ml) % in target ( ng/ml) 20% 100 % below target ( ng/ml) % below target (<100ng/ml) 10% 50 Mean 0% Bangor Cardiff Rhyl Swansea Wrexham All Wales 0

41 % Patients in TSAT range Mean TSAT % 100% 90% 80% 70% Patient Numbers % 77.9% 56.0% 87.0% 65.4% Bangor 100 9% Cardiff 451 0% Rhyl % Swansea % Wrexham % All-Wales % 60% % % 15 30% 20% 10% 44.0% 13.0% 34.6% 10 5 % in target (>=20% % below target (<20%) 0% 0.0% 0 Bangor Cardiff Rhyl Swansea Wrexham All-Wales 0 Mean

42 HB, Ferritin & TSAT: Improvement on All Wales 2012 benchmarks HB: consistent across Wales New thinking : from ESA to Iron 10/21/

43 Share the results of our All-Wales audit of ESA for ACKD Demonstrate the levels of target achievement in accordance with current national standards & comparative benchmarks Consider what we do with these results and how to make best use of this information How we go forward from here on an All Wales level 43

44 10/21/

45 % Pt on IV iron Venofer Cosmofer Monofer Ferinject Rienso Bangor 14% 14% 7% 0% 79% 0% Cardiff Rhyl 31% 5% 0% 0% 95% 0% Swansea 12% 96% 0% 4% 0% 0% Wrexham 11% 96% 0% 0% 4% 0% 10/21/

46 % patients in Hb target range Influeunce of CRP on Hb levels - Unit HD 100% 90% 80% 70% 60% 50% Unit HD Hb > target Unit HD Hb in target Unit HD Hb < target 40% 30% 20% 10% 0% CRP <10 CRP CRP CRP CRP CRP >200 10/21/

47 The pessimist sees difficulties in every opportunity. The optimist sees opportunities in every difficulty Winston Churchill 10/21/

Nephron 2018;139(suppl1): DOI: /

Nephron 2018;139(suppl1): DOI: / Nephron 18;139(suppl1):165 1 DOI: 1.1159/4965 Published online: July 11, 18 UK Renal Registry th Annual Report: Chapter 7 Haemoglobin, Ferritin and Erythropoietin in UK Adult Dialysis Patients in 16: National

More information

Summary of Recommendation Statements Kidney International Supplements (2012) 2, ; doi: /kisup

Summary of Recommendation Statements Kidney International Supplements (2012) 2, ; doi: /kisup http://www.kidney-international.org & 2012 KDIGO Summary of Recommendation Statements Kidney International Supplements (2012) 2, 283 287; doi:10.1038/kisup.2012.41 Chapter 1: Diagnosis and evaluation of

More information

. The median Hb of prevalent patients on HD was g/l.. 59% of HD patients and 55% of PD patients had Hb

. The median Hb of prevalent patients on HD was g/l.. 59% of HD patients and 55% of PD patients had Hb UK Renal Registry 17th Annual Report: Chapter 7 Haemoglobin, Ferritin and Erythropoietin amongst UK Adult Dialysis Patients in 13: National and -specific Analyses Julie Gilg a, Rebecca Evans a, Anirudh

More information

RENAL ANAEMIA. South West Renal Training Scheme Cardiff October 2018

RENAL ANAEMIA. South West Renal Training Scheme Cardiff October 2018 RENAL ANAEMIA South West Renal Training Scheme Cardiff October 2018 Dr Soma Meran Clinical Senior Lecturer and Honorary Consultant Nephrologist, University Hospital of Wales. Aims Biology of renal anaemia

More information

Nephron 2017;000(suppl0): DOI: /

Nephron 2017;000(suppl0): DOI: / Nephron 17;(suppl):165 188 DOI:.1159/444818 Published online: Month??, 17 UK Renal Registry 19th Annual Report: Chapter 7 Haemoglobin, Ferritin and Erythropoietin amongst UK Adult Dialysis Patients in

More information

Nephron 2016;132(suppl1): DOI: /

Nephron 2016;132(suppl1): DOI: / Nephron 16;132(suppl1):169 194 DOI: 10.1159/000444822 Published online: April 19, 16 UK Renal Registry 18th Annual Report: Chapter 8 Haemoglobin, Ferritin and Erythropoietin amongst UK Adult Dialysis Patients

More information

Chapter 7: Adequacy of Haemodialysis and Serum Bicarbonate

Chapter 7: Adequacy of Haemodialysis and Serum Bicarbonate Chapter 7: Adequacy of Haemodialysis and Serum Bicarbonate Summary. The urea reduction ratio (URR) has been rising year on year but now appears to have reached a plateau.. The URR increases the longer

More information

Comment on European Renal Best Practice Position Statement on Anaemia Management in Chronic Kidney Disease.

Comment on European Renal Best Practice Position Statement on Anaemia Management in Chronic Kidney Disease. Comment on European Renal Best Practice Position Statement on Anaemia Management in Chronic Kidney Disease. Goldsmith D, Blackman A, Gabbay F, June 2013 Kidney Disease: Improving Global Outcomes (KDIGO)

More information

ferric carboxymaltose 50mg iron/ml solution for injection/infusion (Ferinject ) SMC No. (463/08) Vifor Pharma UK Ltd

ferric carboxymaltose 50mg iron/ml solution for injection/infusion (Ferinject ) SMC No. (463/08) Vifor Pharma UK Ltd Resubmission ferric carboxymaltose 50mg iron/ml solution for injection/infusion (Ferinject ) SMC No. (463/08) Vifor Pharma UK Ltd 06 May 2011 The Scottish Medicines Consortium (SMC) has completed its assessment

More information

An Audit of Poor Response To Erythropoeitin Therapy. September 1998

An Audit of Poor Response To Erythropoeitin Therapy. September 1998 1 An Audit of Poor Response To Erythropoeitin Therapy September 1998 Prepared By: Nicola Austerberry Renal Audit Facilitator Phil Kalra Consultant Nephrologist 2 1 Introduction The topic for this audit

More information

Efficacy and tolerability of oral Sucrosomial Iron in CKD patients with anemia. Ioannis Griveas, MD, PhD

Efficacy and tolerability of oral Sucrosomial Iron in CKD patients with anemia. Ioannis Griveas, MD, PhD Efficacy and tolerability of oral Sucrosomial Iron in CKD patients with anemia Ioannis Griveas, MD, PhD Anaemia is a state in which the quality and/or quantity of circulating red blood cells are below

More information

Chapter 8: Management of Anaemia in Haemodialysis and Peritoneal Dialysis Patients

Chapter 8: Management of Anaemia in Haemodialysis and Peritoneal Dialysis Patients Chapter 8: Management of Anaemia in Haemodialysis and Peritoneal Dialysis Patients Donald Richardson, Alex Hodsman, Dirk van Schalkwyk, Charlie Tomson and Graham Warwick Summary. 41% of UK patients commence

More information

GUIDELINES FOR ADMINISTRATION OF INTRAVENOUS IRON IN ADULTS WITH CHRONIC KIDNEY DISEASE

GUIDELINES FOR ADMINISTRATION OF INTRAVENOUS IRON IN ADULTS WITH CHRONIC KIDNEY DISEASE GUIDELINES FOR ADMINISTRATION OF INTRAVENOUS IRON IN ADULTS WITH CHRONIC KIDNEY DISEASE Full Title of Guideline: Author (include email and role): Division & Speciality: Scope (Target audience, state if

More information

Chapter 9 Haemoglobin, ferritin and erythropoietin amongst patients receiving dialysis in the UK in 2007: national and centre-specific analyses

Chapter 9 Haemoglobin, ferritin and erythropoietin amongst patients receiving dialysis in the UK in 2007: national and centre-specific analyses Haemoglobin, ferritin and erythropoietin amongst patients receiving dialysis in the UK in 2007: national and centre-specific analyses Donald Richardson a, Daniel Ford b, Julie Gilg b and Andrew J Williams

More information

University Hospitals Coventry & Warwickshire NHS Trust

University Hospitals Coventry & Warwickshire NHS Trust University Hospitals Coventry & Warwickshire NHS Trust Clinical Guideline (full) Anaemia management for chronic kidney disease, peritoneal dialysis, renal transplant and haemodialysis patients E-Library

More information

Chapter 8: Management of Anaemia in Dialysis Patients

Chapter 8: Management of Anaemia in Dialysis Patients Chapter 8: Management of Anaemia in Dialysis Patients Donald Richardson, Daniel Ford, Julie Gilg and Andrew J Williams Summary. In the UK, 40% of patients commenced dialysis therapy with a Hb

More information

Clinical Performance Measures for ESRD Patients. Lana Kacherova, QI Director, ESRD Network th Annual NANT Symposium February 12, 2009

Clinical Performance Measures for ESRD Patients. Lana Kacherova, QI Director, ESRD Network th Annual NANT Symposium February 12, 2009 Clinical Performance Measures for ESRD Patients Lana Kacherova, QI Director, ESRD Network 18 26 th Annual NANT Symposium February 12, 2009 Health Care Quality Improvement Program (HCQIP) The Center for

More information

The FIND-CKD Study Background Study design (Results)

The FIND-CKD Study Background Study design (Results) The FIND-CKD Study Background Study design (Results) The FIND-CKD Study An open-label, multicentre, randomized, 3 arm study comparing the 12-month efficacy and safety of Ferric carboxymaltose (FCM, Ferinject

More information

Advanced Level. Understanding Iron Deficiency Anaemia in Chronic Kidney Disease Information at Advanced Level. Karen Jenkins RN, PGDip HE, MSc

Advanced Level. Understanding Iron Deficiency Anaemia in Chronic Kidney Disease Information at Advanced Level. Karen Jenkins RN, PGDip HE, MSc Advanced Level European Dialysis and Transplant Nurses Association/ European Renal Care Association Understanding Iron Deficiency Anaemia in Chronic Kidney Disease Information at Advanced Level. Karen

More information

ferric carboxymaltose 50mg iron/ml solution for injection/infusion (Ferinject ) SMC No. (463/08) Vifor Pharmaceuticals

ferric carboxymaltose 50mg iron/ml solution for injection/infusion (Ferinject ) SMC No. (463/08) Vifor Pharmaceuticals ferric carboxymaltose 50mg iron/ml solution for injection/infusion (Ferinject ) SMC No. (463/08) Vifor Pharmaceuticals 17 December 2010 The Scottish Medicines Consortium (SMC) has completed its assessment

More information

Chapter 10: Bone Biochemistry: Serum Phosphate, Calcium, Parathyroid Hormone, Albumin and Aluminium

Chapter 10: Bone Biochemistry: Serum Phosphate, Calcium, Parathyroid Hormone, Albumin and Aluminium Chapter 10: Bone Biochemistry: Serum Phosphate, Calcium, Parathyroid Hormone, Albumin and Aluminium Summary. Although serum phosphate control in dialysis patients is unsatisfactory there is a continuing

More information

Oxford Kidney Unit What do my blood and dialysis results mean? Information for patients

Oxford Kidney Unit What do my blood and dialysis results mean? Information for patients Oxford Kidney Unit What do my blood and dialysis results mean? Information for patients page 2 If you are on haemodialysis (HD) or peritoneal dialysis (PD) this leaflet is for you. It will provide you

More information

Future Direction of Anemia Management in ESRD. Jay B. Wish, MD 2008 Nephrology Update March 20, 2008

Future Direction of Anemia Management in ESRD. Jay B. Wish, MD 2008 Nephrology Update March 20, 2008 Future Direction of Anemia Management in ESRD Jay B. Wish, MD 2008 Nephrology Update March 20, 2008 The Evidence Normal Hct Study and CHOIR demonstrate adverse outcomes in ESA patients with target Hgb

More information

EFFECTIVE SHARE CARE AGREEMENT

EFFECTIVE SHARE CARE AGREEMENT Specialist details Patient identifier Name: Tel: EFFECTIVE SHARE CARE AGREEMENT For the specialist use of Erythropoietin Stimulating Agent (ESA) Therapy (formerly known as EPO) for the correction of Anaemia

More information

Chapter Five Clinical indicators & preventive health

Chapter Five Clinical indicators & preventive health Chapter Five Clinical indicators & preventive health The painter who draws merely by practice and by eye, without any reason, is like a mirror which copies every thing placed in front of it without being

More information

Clinical Performance Goals

Clinical Performance Goals Clinical Performance Goals 2011-2012 Clinical Performance Goals 2011-2012 Table of Contents Table of Contents... 1 Health Care Quality Improvement Program... 2 Clinical Performance Measures... 6 Chapter

More information

iron III isomaltoside 1000 (contains 50mg iron per ml) (Diafer ), solution for injection SMC No. (1177/16) Pharmacosmos UK Limited

iron III isomaltoside 1000 (contains 50mg iron per ml) (Diafer ), solution for injection SMC No. (1177/16) Pharmacosmos UK Limited Re-submission iron III isomaltoside 1000 (contains 50mg iron per ml) (Diafer ), solution for injection SMC No. (1177/16) Pharmacosmos UK Limited 13 January 2017 The Scottish Medicines Consortium (SMC)

More information

Cardiovascular disease profile

Cardiovascular disease profile Cardiovascular disease profile Kidney disease Background This chapter of the Cardiovascular disease profiles focuses on kidney disease and is produced by the National Cardiovascular Intelligence Network

More information

Renal association clinical practice guideline on Anaemia of Chronic Kidney Disease

Renal association clinical practice guideline on Anaemia of Chronic Kidney Disease Mikhail et al. BMC Nephrology (2017) 18:345 DOI 10.1186/s12882-017-0688-1 CORRESPONDENCE Renal association clinical practice guideline on Anaemia of Chronic Kidney Disease Ashraf Mikhail 1*, Christopher

More information

No Disclosures 03/20/2019. Learning Objectives. Renal Anemia: The Basics

No Disclosures 03/20/2019. Learning Objectives. Renal Anemia: The Basics Renal Anemia: The Basics Meredith Atkinson, M.D., M.H.S. Associate Professor of Pediatrics Johns Hopkins School of Medicine 16 March 2019 No Disclosures Learning Objectives At the end of this session the

More information

NURSE OR PHARMACIST-LED ANEMIA MANAGEMENT PROTOCOL

NURSE OR PHARMACIST-LED ANEMIA MANAGEMENT PROTOCOL CANN-NET ANEMIA MANAGEMENT FOR HEMODIALYSIS CENTRES NURSE OR PHARMACIST-LED ANEMIA MANAGEMENT PROTOCOL TABLE OF CONTENTS: Hemoglobin Status Assessment ------------------------------------------- Page 1

More information

The US K/DOQI guideline states: The target range for haemoglobin (haematocrit) should be 11 g/dl (33%) to 12 g/dl (36%).

The US K/DOQI guideline states: The target range for haemoglobin (haematocrit) should be 11 g/dl (33%) to 12 g/dl (36%). Chapter 8: Haemoglobin Summary There is continued improvement in anaemia management in centres submitting data to the Registry, 81% of haemodialysis and 86% of peritoneal dialysis patients achieving the

More information

All Wales nutrition screening audit: nephrology inpatients.

All Wales nutrition screening audit: nephrology inpatients. All Wales nutrition screening audit: nephrology inpatients. Starter Malnutrition- a deficiency of energy, protein & other nutrients that causes adverse effects on the body (shape, size & composition),

More information

Northern Treatment Advisory Group

Northern Treatment Advisory Group Northern Treatment Advisory Group Ferric Maltol (Feraccru ) for the treatment of iron deficiency Lead author: Daniel Hill Regional Drug & Therapeutics Centre (Newcastle) September 2018 2018 Summary Iron

More information

Chapter 7: Haemoglobin. Summary. Introduction. Inclusion criteria

Chapter 7: Haemoglobin. Summary. Introduction. Inclusion criteria Chapter 7: Haemoglobin Summary Improvement in haemoglobin concentrations of patients receiving dialysis treatment continued in 2002. 82% of haemodialysis patients and 88% of peritoneal dialysis patients

More information

patients and 66% of peritoneal dialysis patients had a systolic blood pressure within the 90th percentile

patients and 66% of peritoneal dialysis patients had a systolic blood pressure within the 90th percentile Renal Registry 5th Annual Report: Chapter 7 Clinical, Haematological and Biochemical Parameters in Patients receiving Renal Replacement Therapy in Paediatric s in the in 2: national and centre-specific

More information

Lesson #7: Quality Assessment and Performance Improvement

Lesson #7: Quality Assessment and Performance Improvement ESRD Update: Transitioning to New ESRD Conditions for Coverage Student Manual Lesson #7: Quality Assessment and Performance Improvement Learning Objectives At the conclusion of this lesson, you will be

More information

Effective Health Care Program

Effective Health Care Program Comparative Effectiveness Review Number 83 Effective Health Care Program Biomarkers for Assessing and Managing Iron Deficiency Anemia in Late-Stage Chronic Kidney Disease Executive Summary Background Chronic

More information

Beaumont Hospital Department of Transplantation, Urology and Nephrology. Guideline for administering Intravenous Ferinject in the Renal Unit

Beaumont Hospital Department of Transplantation, Urology and Nephrology. Guideline for administering Intravenous Ferinject in the Renal Unit Beaumont Hospital Department of Transplantation, Urology and Nephrology Guideline for administering Intravenous Ferinject in the Renal Unit Document Number: 18 Reason for Change Review and update Original

More information

NATIONAL QUALITY FORUM Renal EM Submitted Measures

NATIONAL QUALITY FORUM Renal EM Submitted Measures NATIONAL QUALITY FORUM Renal EM Submitted Measures Measure ID/ Title Measure Description Measure Steward Topic Area #1662 Percentage of patients aged 18 years and older with a diagnosis of CKD ACE/ARB

More information

Introduction The Role of the Kidneys Drugs used in Renal Disease Drugs and Dialysis Renal Pharmacy Team

Introduction The Role of the Kidneys Drugs used in Renal Disease Drugs and Dialysis Renal Pharmacy Team Introduction The Role of the Kidneys Drugs used in Renal Disease Drugs and Dialysis Renal Pharmacy Team Drugs play a major role in both treating and causing renal disease Doses of some drugs need to be

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Venofer) Reference Number: CP.PHAR.167 Effective Date: 07.01.18 Last Review Date: 02.18 Line of Business: Oregon Health Plan Coding Implications Revision Log See Important Reminder at

More information

The Changing Clinical Landscape of Anemia Management in Patients With CKD: An Update From San Diego Presentation 1

The Changing Clinical Landscape of Anemia Management in Patients With CKD: An Update From San Diego Presentation 1 Presentation 1 The following is a transcript from a web-based CME-certified multimedia activity. Interactivity applies only when viewing the activity online. This activity is supported by educational grants

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Chronic kidney disease: early identification and management of adults with chronic kidney disease in primary and secondary

More information

National Comparative Audit of red cell transfusion in Medical Patients Part Two

National Comparative Audit of red cell transfusion in Medical Patients Part Two National Comparative Audit of red cell transfusion in Medical Patients Part Two Dr. Kate Pendry, Project Clinical Lead John Grant-Casey, Project Manager August 2013 Part One 9216 cases from 181 sites (90%

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium epoetin zeta, 1000 IU/0.3ml, 2000 IU/0.6ml, 3000 IU/0.9ml, 4000 IU/0.4ml, 5000 IU/0.5ml, 6000 IU/0.6ml, 8000 IU/0.8ml, 10,000 IU/1.0ml, 20,000 IU/0.5ml, 30,000 IU/0.75ml and

More information

Clinical Performance Goals

Clinical Performance Goals Clinical Performance Goals 2012-2013 Clinical Performance Goals 2012-2013 Table of Contents Table of Contents... 1 Health Care Quality Improvement Program... 2 ESRD Quality Incentive Program (QIP)... 5

More information

Renal anaemia. Information for you. Follow us on Find us on Facebook at Visit our website:

Renal anaemia. Information for you. Follow us on Find us on Facebook at   Visit our website: Renal anaemia Information for you Follow us on Twitter @NHSaaa Find us on Facebook at www.facebook.com/nhsaaa Visit our website: www.nhsaaa.net All our publications are available in other formats This

More information

Maintenance intravenous iron therapy in pediatric hemodialysis patients Morgan H E, Gautam M, Geary D F

Maintenance intravenous iron therapy in pediatric hemodialysis patients Morgan H E, Gautam M, Geary D F Maintenance intravenous iron therapy in pediatric hemodialysis patients Morgan H E, Gautam M, Geary D F Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion

More information

ANEMIA IN CANCER ROLE OF IV IRON

ANEMIA IN CANCER ROLE OF IV IRON ANEMIA IN CANCER ROLE OF IV IRON IRON DEFICIENCY Absolute vs functional Absolute iron deficiency µ anemia = no iron stores : ferritin < 20 µg/l in N individual < 100 µg/l in infl/cancer patient Functional

More information

Irish Practice Nurses Association Annual Conference Tullamore Court Hotel OCTOBER 6 th 2012

Irish Practice Nurses Association Annual Conference Tullamore Court Hotel OCTOBER 6 th 2012 Irish Practice Nurses Association Annual Conference Tullamore Court Hotel OCTOBER 6 th 2012 Susan McKenna Renal Clinical Nurse Specialist Cavan General Hospital Renal patient population ACUTE RENAL FAILURE

More information

New Zealand. Dialysis and Transplantation Audit

New Zealand. Dialysis and Transplantation Audit New Zealand Dialysis and Transplantation Audit Report for New Zealand Nephrology Services on behalf of the National Renal Advisory Board Grant Pidgeon Standards and Audit Subcommittee July 2012 Establishment

More information

CHAPTER 5. Haemodialysis. Kevan Polkinghorne Hannah Dent Aarti Gulyani Kylie Hurst Stephen McDonald

CHAPTER 5. Haemodialysis. Kevan Polkinghorne Hannah Dent Aarti Gulyani Kylie Hurst Stephen McDonald CHAPTER Haemodialysis Kevan Polkinghorne Hannah Dent Aarti Gulyani Kylie Hurst Stephen McDonald STOCK AND FLOW AUSTRALIA The annual stock and flow of HD patients during the period - is shown in Figures.,.

More information

Chapter 6: Adequacy of haemodialysis (Urea reduction ratio)

Chapter 6: Adequacy of haemodialysis (Urea reduction ratio) Chapter 6: Adequacy of haemodialysis (Urea reduction ratio) Summary In England & Wales a uniform method of measuring the post dialysis urea sample (as suggested in the 1 Renal Association standards document)

More information

IN-CENTER HEMODIALYSIS (HD) CLINICAL PERFORMANCE MEASURES DATA COLLECTION FORM 2006

IN-CENTER HEMODIALYSIS (HD) CLINICAL PERFORMANCE MEASURES DATA COLLECTION FORM 2006 IN-CENTER HEMODIALYSIS (HD) CLINICAL PERFORMANCE MEASURES DATA COLLECTION FORM 2006 PATIENT IDENTIFICATION [Before completing please read instructions at the bottom of this page and on pages 5 and 6] MAKE

More information

K atching Up with KDOQI: Clinical Practice Guidelines & Clinical Practice Recommendations for Anemia of Chronic Kidney Disease 2006

K atching Up with KDOQI: Clinical Practice Guidelines & Clinical Practice Recommendations for Anemia of Chronic Kidney Disease 2006 K atching Up with KDOQI: Clinical Practice Guidelines & Clinical Practice Recommendations for Anemia of Chronic Kidney Disease 2006 Why new guidelines? Rationale for KDOQI Anemia 2006 Expand scope to all

More information

EPO e Ferro in Emodialisi: Il PBM al suo esordio. Lucia Del Vecchio. Divisione di Nefrologia e Dialisi Ospedale A. Manzoni, ASST Lecco

EPO e Ferro in Emodialisi: Il PBM al suo esordio. Lucia Del Vecchio. Divisione di Nefrologia e Dialisi Ospedale A. Manzoni, ASST Lecco PATIENT BLOOD MANAGEMENT DALLA TEORIA ALLA PRATICA 16 FEBBRAIO 2018 EPO e Ferro in Emodialisi: Il PBM al suo esordio Lucia Del Vecchio Divisione di Nefrologia e Dialisi Ospedale A. Manzoni, ASST Lecco

More information

Clinical Policy: Iron Sucrose (Venofer) Reference Number: CP.PHAR.167

Clinical Policy: Iron Sucrose (Venofer) Reference Number: CP.PHAR.167 Clinical Policy: (Venofer) Reference Number: CP.PHAR.167 Effective Date: 03/16 Last Review Date: 03/17 Revision Log Coding Implications See Important Reminder at the end of this policy for important regulatory

More information

University Hospitals of Leicester NHS Trust ANAEMIA_IRON THERAPY FOR ANAEMIA OF CHRONIC KIDNEY DISEASE. RRCV CMG Nephrology Service

University Hospitals of Leicester NHS Trust ANAEMIA_IRON THERAPY FOR ANAEMIA OF CHRONIC KIDNEY DISEASE. RRCV CMG Nephrology Service 1. Introduction Anaemia is a common complication of chronic kidney disease with the prevalence of anaemia increasing as glomerular filtration rate falls. The management of anaemia in CKD for both non-dialysis

More information

ANAEMIA MANAGEMENT: THE KDIGO RECOMMENDATIONS Patrick S. Parfrey, St. John s, Canada

ANAEMIA MANAGEMENT: THE KDIGO RECOMMENDATIONS Patrick S. Parfrey, St. John s, Canada ANAEMIA MANAGEMENT: THE KDIGO RECOMMENDATIONS Patrick S. Parfrey, St. John s, Canada Chair: Kai- Uwe Eckardt, Erlangen, Germany Pierre- Yves Martin, Geneva, Switzerland Prof. Patrick S. Parfrey Division

More information

Chapter 10: Serum Calcium, Phosphate and Parathyroid Hormone

Chapter 10: Serum Calcium, Phosphate and Parathyroid Hormone Chapter 1: Serum Calcium, Phosphate and Parathyroid Hormone Summary Results for corrected calcium are highly dependent on serum albumin measurement. Units using the BCP method of albumin measurement have

More information

Iron metabolism anemia and beyond. Jacek Lange Perm, 8 October 2016

Iron metabolism anemia and beyond. Jacek Lange Perm, 8 October 2016 Iron metabolism anemia and beyond Jacek Lange Perm, 8 October 2016 1 Overview 1. Iron metabolism 2. CKD Chronic Kidney Disease 3. Iron deficiency beyond anemia and CKD 4. Conclusions 2 Why iron deficiency

More information

Chronic Kidney Disease (CKD) and egfr: Decision and Dilemma. Dr Bhavna K Pandya Consultant Nephrologist University Hospital Aintree

Chronic Kidney Disease (CKD) and egfr: Decision and Dilemma. Dr Bhavna K Pandya Consultant Nephrologist University Hospital Aintree Chronic Kidney Disease (CKD) and egfr: Decision and Dilemma Dr Bhavna K Pandya Consultant Nephrologist University Hospital Aintree Topics CKD background egfr background Patient with egfr Referral Guidelines

More information

Study of Management of anemia in Chronic Kidney Disease Patients

Study of Management of anemia in Chronic Kidney Disease Patients Review Article Study of Management of anemia in Chronic Kidney Disease Patients Meby Susan Mathew, Nama Ravi Sneha Keerthi, Neelathahalli Kasturirangan Meera* Meera N.K, Visveswarapura Institute of Pharmaceutical

More information

ADVANCES. Annual reports from the Centers for. In Anemia Management. Anemia Management in the United States: Is There Opportunity for Improvement?

ADVANCES. Annual reports from the Centers for. In Anemia Management. Anemia Management in the United States: Is There Opportunity for Improvement? ADVANCES Vol. 1 No.1 22 We are pleased to introduce our newest NPA publication, Advances in Anemia Management. This quarterly publication will address contemporary issues relating to the treatment of anemia

More information

Guideline Summary NGC-6019

Guideline Summary NGC-6019 NGC banner Guideline Summary NGC-6019 Guideline Title (1) KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. (2) 2007 update of hemoglobin target.

More information

Transplant First: Addressing inequality in access to Kidney Transplantation in the West Midlands

Transplant First: Addressing inequality in access to Kidney Transplantation in the West Midlands Project Mandate Transplant First: Addressing inequality in access to Kidney Transplantation in the West Midlands West Midlands Cardiovascular Strategic Clinical Network Project Mandate Transplant First:

More information

Literature Scan: Erythropoiesis Stimulating Agents

Literature Scan: Erythropoiesis Stimulating Agents Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Non-Medical Authorisation Course TRANSFUSION ALTERNATIVES. East Midlands Regional Transfusion Committee

Non-Medical Authorisation Course TRANSFUSION ALTERNATIVES. East Midlands Regional Transfusion Committee Non-Medical Authorisation Course TRANSFUSION ALTERNATIVES Janice Smith Matron Transfusion Specialist (Slides Leanne Hostler & Ant Jackson!) Aims Why we need to consider alternatives? What alternatives

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium epoetin theta, 1,000 IU/0.5mL, 2,000 IU/0.5mL, 3,000 IU/0.5mL, 4,000 IU/0.5mL, 5,000 IU/0.5mL, 10,000 IU/1mL, 20,000 IU/1mL, 30,000 IU/1mL solution for injection in pre filled

More information

Anemia Management in Peritoneal Dialysis Patients Pranay Kathuria, FACP, FASN

Anemia Management in Peritoneal Dialysis Patients Pranay Kathuria, FACP, FASN Anemia Management in Peritoneal Dialysis Patients Pranay Kathuria, FACP, FASN Professor of Medicine Director, Division of Nephrology and Hypertension University of Oklahoma College of Medicine Definition

More information

Pre-operative Anaemia Colorectal and Orthopaedic Surgery

Pre-operative Anaemia Colorectal and Orthopaedic Surgery Pre-operative Anaemia Colorectal and Orthopaedic Surgery Dr Simon Rang Consultant Anaesthetist East Kent Hospitals NHS Trust Dreamland Pre-operative Anaemia Anaemia is a perioperative risk factor Perioperative

More information

Management of anemia in CKD. Masaomi Nangaku Division of Nephrology and Endocrinology the University of Tokyo Graduate School of Medicine, Japan

Management of anemia in CKD. Masaomi Nangaku Division of Nephrology and Endocrinology the University of Tokyo Graduate School of Medicine, Japan Management of anemia in CKD Masaomi Nangaku Division of Nephrology and Endocrinology the University of Tokyo Graduate School of Medicine, Japan Shiga toxin Kiyoshi Shiga 1871-1957 Shiga toxin binds to

More information

Medicines for anaemia and mineral bone disease

Medicines for anaemia and mineral bone disease Patient Information: Medicines NHS Logo here Medicines for anaemia and mineral bone disease Health & care information you can trust The Information Standard Certified Member Working together for better

More information

Intravenous Iron Requirement in Adult Hemodialysis Patients

Intravenous Iron Requirement in Adult Hemodialysis Patients Intravenous Iron Requirement in Adult Hemodialysis Patients Timothy V. Nguyen, PharmD The author is a clinical pharmacy specialist with Holy Name Hospital in Teaneck, New Jersey. He is also an adjunct

More information

Public Assessment Report Scientific discussion. Monofer 100 mg/ml solution for injection/infusion (iron(iii) isomaltoside 1000) SE/H/734/01/DC

Public Assessment Report Scientific discussion. Monofer 100 mg/ml solution for injection/infusion (iron(iii) isomaltoside 1000) SE/H/734/01/DC Public Assessment Report Scientific discussion Monofer 100 mg/ml solution for injection/infusion (iron(iii) isomaltoside 1000) SE/H/734/01/DC This module reflects the scientific discussion for the approval

More information

SYNOPSIS. Issue Date: 04 February 2009 Document No.: EDMS -USRA

SYNOPSIS. Issue Date: 04 February 2009 Document No.: EDMS -USRA SYNOPSIS Issue Date: 04 February 2009 Document No.: EDMS -USRA-10751204 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient(s) Johnson & Johnson Pharmaceutical Research & Development,

More information

PERITONEAL DIALYSIS CLINICAL PERFORMANCE MEASURES DATA COLLECTION FORM 2006

PERITONEAL DIALYSIS CLINICAL PERFORMANCE MEASURES DATA COLLECTION FORM 2006 PERITONEAL DIALYSIS CLINICAL PERFORMANCE MEASURES DATA COLLECTION FORM 2006 PATIENT IDENTIFICATION [Before completing please read instructions at the bottom of this page and on pages 5 and 6] MAKE CORRECTIONS

More information

Department of Renal Medicine St George & Sutherland Hospitals. Annual Report. and. Quality Indicators

Department of Renal Medicine St George & Sutherland Hospitals. Annual Report. and. Quality Indicators Department of Renal Medicine St George & Sutherland Hospitals 2017 Annual Report and Quality Indicators Introduction It gives me great pleasure to present the 2017 Annual Report of the Department of Renal

More information

CHAPTER 6 PERITONEAL DIALYSIS. Fiona Brown Aarti Gulyani Stephen McDonald Kylie Hurst Annual Report 35th Edition

CHAPTER 6 PERITONEAL DIALYSIS. Fiona Brown Aarti Gulyani Stephen McDonald Kylie Hurst Annual Report 35th Edition CHAPTER 6 PERITONEAL DIALYSIS Fiona Brown Aarti Gulyani Stephen McDonald Kylie Hurst 212 Annual Report 35th Edition PERITONEAL DIALYSIS ANZDATA Registry 212 Report STOCK AND FLOW AUSTRALIA Peritoneal dialysis

More information

REIMBURSEMENT AND ITS IMPACT ON YOUR DIALYSIS PROGRAM Tony Messana Executive Director Renal Services St. Joseph Hospital - Orange

REIMBURSEMENT AND ITS IMPACT ON YOUR DIALYSIS PROGRAM Tony Messana Executive Director Renal Services St. Joseph Hospital - Orange REIMBURSEMENT AND ITS IMPACT ON YOUR DIALYSIS PROGRAM Tony Messana Executive Director Renal Services St. Joseph Hospital - Orange Agenda History of the Medicare ESRD Program Cost of Care for ESRD Patients

More information

Comparison of Erythropoietin and Darbepoetin in Chronic Kidney Disease Patients in a Tertiary Care Hospital

Comparison of Erythropoietin and Darbepoetin in Chronic Kidney Disease Patients in a Tertiary Care Hospital Human Journals Research Article July 2017 Vol.:9, Issue: 4 All rights are reserved by Pournami A S et al. Comparison of Erythropoietin and Darbepoetin in Chronic Kidney Disease Patients in a Tertiary Care

More information

Update on the management of iron deficiency

Update on the management of iron deficiency Update on the management of iron deficiency Outline Need to improve management & avoid transfusion Diagnosis & investigation Oral iron & IV iron Tools & resources No conflicts of interest All natural

More information

FDA Advisory Committee Briefing Document

FDA Advisory Committee Briefing Document FDA Advisory Committee Briefing Document Drug Safety and Risk Management Committee February 1, 2008 Prepared by the Division of Medical Imaging and Hematology Products/Office of Oncology Drug Products/Office

More information

Variable Included. Excluded. Included. Excluded

Variable Included. Excluded. Included. Excluded Table S1. Baseline characteristics of patients included in the analysis and those excluded patients because of missing baseline serumj bicarbonate levels, stratified by dialysis modality. Variable HD patients

More information

Epogen / Procrit. Epogen / Procrit (epoetin alfa) Description

Epogen / Procrit. Epogen / Procrit (epoetin alfa) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.10.06 Section: Prescription Drugs Effective Date: April1, 2014 Subject: Epogen / Procrit Page: 1 of 7

More information

Current situation and future of renal anemia treatment. FRANCESCO LOCATELLI

Current situation and future of renal anemia treatment. FRANCESCO LOCATELLI Antalya May 20, 2010 12 National Congress of Turkish Society of Hypertension and Renal Disease Current situation and future of renal anemia treatment. FRANCESCO LOCATELLI Department of Nephrology, Dialysis

More information

8/22/1395 Dr. F. Moeinzadeh

8/22/1395 Dr. F. Moeinzadeh 1 How I treat CKD Dr. Firouzeh Moeinzadeh Táá áàtçà ÑÜÉyxááÉÜ Éy axñ{üéäézç \áyt{tç hç äxüá àç Éy `xw vtä fv xçvxá 2 Aim of this lesson How I diagnosis a CKD patient? How I follow a CKD patient? How I

More information

Guidelines on Anaemia Management in Patients with Chronic Kidney Disease (CKD)

Guidelines on Anaemia Management in Patients with Chronic Kidney Disease (CKD) Guidelines on Anaemia Management in Patients with Chronic Kidney Disease (CKD) This guideline is for use in adult patients with an estimated Glomerular Filtration Rate (egfr) of less than 60ml/min/1.73m

More information

OPTA-therapy with iron and erythropoiesis-stimulating agents in chronic kidney disease

OPTA-therapy with iron and erythropoiesis-stimulating agents in chronic kidney disease Nephrol Dial Transplant (2007) 22 [Suppl 3]: iii2 iii6 doi:10.1093/ndt/gfm014 OPTA-therapy with iron and erythropoiesis-stimulating agents in chronic kidney disease W. H. Ho rl 1, I. C. Macdougall 2, J.

More information

Chapter 10: Factors which may influence cardiovascular disease blood pressure and serum cholesterol

Chapter 10: Factors which may influence cardiovascular disease blood pressure and serum cholesterol Chapter 10: Factors which may influence cardiovascular disease blood pressure and serum cholesterol Summary. Blood pressure returns to the Renal Registry continue to be poor from some centres.. In England

More information

Dialysis and Transplantation Audit

Dialysis and Transplantation Audit New Zealand Dialysis and Transplantation Audit and A summary report of activity for New Zealand nephrology services Dr Suetonia Palmer On behalf of the National Renal Advisory Board NRAB Standard and Audits

More information

Intravenous Iron: A Good Thing Made Better? Marilyn Telen, MD Wellcome Professor of Medicine Duke University

Intravenous Iron: A Good Thing Made Better? Marilyn Telen, MD Wellcome Professor of Medicine Duke University Intravenous Iron: A Good Thing Made Better? Marilyn Telen, MD Wellcome Professor of Medicine Duke University Use of IV Iron There are increasing data regarding safety of IV iron. IV iron is superior to

More information

ROYAL WOLVERHAMPTON HOSPITALS NHS TRUST

ROYAL WOLVERHAMPTON HOSPITALS NHS TRUST ROYAL WOLVERHAMPTON HOSPITALS NHS TRUST SHARED CARE PROTOCOL FOR ERYTHROPOIETIN USE 2016 New Cross Hospital Dr J Odum Dr P B Rylance Dr P Carmichael Dr S Acton Dr B Ramakrishna Walsall Manor Hospital Dr

More information

Once-weekly darbepoetin alfa is as effective as three-times weekly epoetin

Once-weekly darbepoetin alfa is as effective as three-times weekly epoetin Artigo Original ONCE-WEEKLY DARBEPOETIN ALFA IS AS EFFECTIVE AS THREE-TIMES WEEKLY EPOETIN Rev Port Nefrol Hipert 2004; 18 (1): 33-40 Once-weekly darbepoetin alfa is as effective as three-times weekly

More information

Smoking Cessation Profile: Betsi Cadwaladr University Health Board 2012/2013

Smoking Cessation Profile: Betsi Cadwaladr University Health Board 2012/2013 Smoking Cessation Profile: Betsi Cadwaladr University Health Board 2012/2013 Authors: Delyth Jones, Principal Public Health Officer, Claire Jones, Public Health Intelligence Specialist & Dr Chris Stockport,

More information

Clinical Practice Guideline Anaemia of Chronic Kidney Disease

Clinical Practice Guideline Anaemia of Chronic Kidney Disease Clinical Practice Guideline Anaemia of Chronic Kidney Disease Final Version: June 2017 Review Date: June 2022 Authors: Dr Ashraf Mikhail Consultant Nephrologist, Abertawe Bro Morgannwg University Health

More information